FDA Arthritis Advisory Committee meeting.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001310:Auranofin; D006051:Aurothioglucose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011422:Propionates; C011677:benoxaprofen; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold